CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD)

A parallel-group treatment, proof-of-concept Phase 2, multicenter, double-blind, randomized 2 arm clinical trial to investigate the efficacy and safety of subcutaneous NT 201 injections compared with placebo injections in decreasing pain intensity in male and female participants aged 18 years and older with moderate or severe chronic neuropathic pain due to postherpetic neuralgia or peripheral nerve injury.

RELIEVE (RandomizEd triaL of Intravesical xEomin for incontinence via the VibE system) - a randomized, prospective, multicenter, double blind, placebo and sham controlled study to assess the safety and efficacy of NT 201 intravesical administration using Vibe System in the treatment of female participants suffering from idiopathic overactive bladder

Botulinumtoxin A as a treatment for myalgia and myofacial pain in patient with temporomandibulardisorders – a quality study associated to a new treatment routine.

A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine (MINT-E)

A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine (MINT-C)